reports
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Quad/Graphics, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 April 2024 in which Moody's reassessed the appropriateness of the ratings in the con...
TELA Bio to Announce First Quarter 2024 Financial Results
TELA Bio to Announce First Quarter 2024 Financial Results MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex...
TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and roboti...
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affai...
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein ...
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spannin...
Avalo Reports 2023 Financial Results and Provides Business Updates
Avalo Reports 2023 Financial Results and Provides Business Updates Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 millionTopline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023....
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financin...
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq...
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues an...
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Reported revenue of $17.0 million in the fourth quarter and $58.5 mil...
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-...
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of LIQUIFIX FIX8™ Laparoscopic and LIQUIFIX Precision™ Open Hernia Mesh Fixation Devices. LIQUIFIX FIX8 is indicated for minim...
TELA Bio Announces Sale of Distribution Rights for Wound Care Product ...
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX TELA Bio to receive at least $8 million and up to $12 million in total consideration MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the sale of its distribution rights related to NIVIS Fibrillar Collagen Pack to Atlanta-based MiMedx Group, Inc. (“MIMEDX”). As consideration for the sale, MIMEDX will make an initial $5.0 million payment and additional future pa...
Coty remporte le prix Euronext de la meilleure introduction en bourse ...
PARIS--(BUSINESS WIRE)-- Coty (NYSE: COTY) (Paris: COTY), l'un des plus grands acteurs mondiaux du secteur de la beauté, avec un portefeuille de marques emblématiques de parfums, de maquillage et de soins, a remporté le prix Euronext 2024 de la meilleure introduction en bourse dans la catégorie Large Cap lors de la 12e conférence annuelle d'Euronext qui s'est tenue le 19 mars 2024 à Paris. Ce prix récompense le succès de l'introduction en bourse de Coty, la plus importante à ce jour sur Euronext Growth®. La double cotation sur Euronext Paris a été un franc succès pour l'entreprise, levant 33...
Coty Wins this year’s Euronext Best listing Award in the Large Cap cat...
PARIS--(BUSINESS WIRE)-- Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, has won this year’s Euronext Best Listing Award in the Large Cap category, at the 12th edition of the Euronext Annual Conference held on March 19, 2024 in Paris. The award recognizes the success of Coty's global offering, the largest to date on Euronext Growth®. The secondary listing on Euronext Paris was a resounding success for the company, raising €339.2 million, making it the 47th listing on Euronext...
- Jonathan Moreland
SEDG SOLAREDGE TECHNOLOGIES INC.
PRGO PERRIGO CO. PLC
GOGO GOGO INC.
D DOMINION ENERGY INC
CTRN CITI TRENDS INC.
CLFD CLEARFIELD INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
HWBK HAWTHORN BANCSHARES
FMC FMC CORPORATION
RIGN TRANSOCEAN LTD.
SPWR SUNPOWER CORPORATION
AFT APOLLO SENIOR FLOATING RATE FUND INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
HCC WARRIOR MET COAL INC.
RBB RBB BANCORP
AXR AMREP
FSK FS KKR CAPITAL CORP
KSM DWS STRATEGIC MUNICIPAL INCOME TRUST
ETNB 89BIO
PCB PACIFIC CITY FINANCIAL CORP
BSBK BOGOTA FINANCIAL CORP.
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
THRY THRYV HOLDINGS
ABCL ABCELLERA BIOLOGICS
LSEA LANDSEA HOMES CORP (A)
LUMN LUMEN TECHNOLOGIES INC.
SLRC SOLAR CAPITAL LTD.
ONDS ONDAS HOLDINGS
PFX PHENIXFIN CORP
WES WESTERN MIDSTREAM PARTNERS LP
ABSI ABSCI CORP
VPV INVESCO PA VALUE MUNI INC TST
GATO SUNSHINE SILVER MINING AND REFINING CORP
LSXMA LIBERTY SIRIUSXM GROUP
LSXMK BURKE HERBERT FINANCIAL SERVICES CORP
BHRB ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS
MDRX INC.
Coty Inc: 1 director
A director at Coty Inc sold 159,982 shares at 12.609USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- Jonathan Moreland
Calvin Klein Fragrances annonce qu'Idris et Sabrina Elba seront les ég...
NEW YORK--(BUSINESS WIRE)-- Calvin Klein, Inc, filiale détenue à part entière par PVH Corp (NYSE : PVH), et Calvin Klein Fragrances, division de Coty Inc (NYSE : COTY), ont dévoilé aujourd'hui que l'acteur et musicien Idris Elba ainsi que son épouse Sabrina Elba, mannequin et militante des droits de l'homme, sont les égéries de Calvin Klein ETERNITY AROMATIC ESSENCE, le nouvel ajout au portefeuille de parfums ETERNITY. Ce communiqué de presse contient des éléments multimédias. Voir le communiqué complet ici : Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin K...
Calvin Klein Fragrances announces Idris and Sabrina Elba as the face o...
NEW YORK--(BUSINESS WIRE)-- Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin Klein ETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITY fragrance portfolio. This press release features multimedia. View the full release here: Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Busines...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.